Mosseri Marlio Charles's Form 4/A amendment
AmendedNuvectis Pharma, Inc. (NVCT) · filed May 12, 2025
- Accession no.
- 0001104659-25-047089
- Filed
- May 12, 2025
- Trade date
- May 8-9, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
- Original filed
- May 9, 2025
This filing lists 6 non-derivative transactions. It carries over 5 transactions from the original filing that it did not restate. Open-market purchases total $460.4K. It was filed 4 days after the trade.
This amendment restates part of 0001104659-25-046882 (filed May 9, 2025). The transactions it did not restate still count and are listed below.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mosseri Marlio CharlesCIK 0001806384 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 8, 2025 | Common Stock | PPurchaseAcquired | +100 | $8.99F2 | +$899 | 2,909,032 | Indirect | |
| May 8, 2025 | Common Stock | PPurchaseAcquired | +100 | $8.71F2 | +$871 | 2,909,132 | Indirect | |
| May 8, 2025 | Common Stock | PPurchaseAcquired | +2,400 | $8.97F2 | +$21,528 | 2,911,532 | Indirect | |
| May 9, 2025 | Common Stock | PPurchaseAcquired | +9,850 | $8.95F3 | +$88,157.5 | 2,921,382 | Indirect | |
| May 9, 2025 | Common Stock | PPurchaseAcquired | +9,817 | $8.90F3 | +$87,371.3 | 2,931,199 | Indirect | |
| May 9, 2025 | Common Stock | PPurchaseAcquired | +5,395 | $8.98F3 | +$48,447.1 | 2,936,594 | Indirect |
Carried over from the original filing
This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.
From 0001104659-25-046882 (filed May 9, 2025).
Non-derivative securities (Table I)
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 6, 2025 | Common Stock | PPurchaseAcquired | +2,340 | $8.40 | +$19,656 | 2,886,461 | Indirect | |
| May 6, 2025 | Common Stock | PPurchaseAcquired | +10,104 | $8.64 | +$87,298.56 | 2,896,565 | Indirect | |
| May 7, 2025 | Common Stock | PPurchaseAcquired | +2,703 | $8.40 | +$22,705.2 | 2,899,268 | Indirect | |
| May 7, 2025 | Common Stock | PPurchaseAcquired | +9,614 | $8.64 | +$83,064.96 | 2,908,882 | Indirect | |
| May 8, 2025 | Common Stock | PPurchaseAcquired | +50 | $8.65 | +$432.5 | 2,908,932 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Charles Mosseri Marlio is the beneficial owner of Emerald Hill Ventures SARL.
- F2
The original Form 4, filed on May 9, 2025, is being amended by this Form 4 amendment to correct the price of securities acquired by the reporting in the reported transactions.
Referenced by the price of 3 transactions in Table I.
- F3
The original Form 4, filed on May 9, 2025, is being amended by this Form 4 amendment to include transactions that occurred on May 9, 2025.
Referenced by the price of 3 transactions in Table I.